[{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"5b6f5e90-5c5a-4cbe-a9af-ed1c1a32c726","acronym":"","url":"https://clinicaltrials.gov/study/NCT04975152","created_at":"2021-07-23T13:52:34.008Z","updated_at":"2025-02-25T14:02:26.800Z","phase":"Phase 1","brief_title":"Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma","source_id_and_acronym":"NCT04975152","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"f9665a10-dce3-43c7-a423-8c44b5bd6d32","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944941","created_at":"2021-01-18T19:25:25.225Z","updated_at":"2025-02-25T14:15:21.839Z","phase":"Phase 2","brief_title":"Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer","source_id_and_acronym":"NCT03944941","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/17/2019","start_date":" 06/17/2019","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-18"},{"id":"42d2a0f4-bf25-41be-9b41-ecad4c959f5d","acronym":"CK-301-101","url":"https://clinicaltrials.gov/study/NCT03212404","created_at":"2021-01-18T15:50:41.447Z","updated_at":"2025-02-25T16:59:32.024Z","phase":"Phase 1","brief_title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","source_id_and_acronym":"NCT03212404 - CK-301-101","lead_sponsor":"Checkpoint Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unloxcyt (cosibelimab-ipdl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"c307870e-5bd7-4085-ba24-fcc2ef88aa91","acronym":"","url":"https://clinicaltrials.gov/study/NCT04710498","created_at":"2021-01-19T20:52:20.937Z","updated_at":"2025-02-25T17:00:54.520Z","phase":"Phase 2","brief_title":"Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma","source_id_and_acronym":"NCT04710498","lead_sponsor":"Stanford University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 02/07/2024","primary_completion_date":" 02/07/2024","study_txt":" Completion: 02/15/2024","study_completion_date":" 02/15/2024","last_update_posted":"2025-02-03"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"88834346-c6d3-46c6-ab88-e163b86f1000","acronym":"UNSCARRed","url":"https://clinicaltrials.gov/study/NCT03737721","created_at":"2024-06-15T04:01:20.965Z","updated_at":"2024-07-02T16:34:25.725Z","phase":"Phase 2","brief_title":"The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy","source_id_and_acronym":"NCT03737721 - UNSCARRed","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/12/2019","start_date":" 04/12/2019","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 12/08/2024","study_completion_date":" 12/08/2024","last_update_posted":"2024-06-14"},{"id":"351db7f3-6d9a-4613-9f48-4b25eb1e0b71","acronym":"","url":"https://clinicaltrials.gov/study/NCT03894618","created_at":"2021-01-18T19:11:01.852Z","updated_at":"2024-07-02T16:34:26.954Z","phase":"Phase 1","brief_title":"SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT03894618","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK fusion","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-279252"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 05/04/2023","primary_completion_date":" 05/04/2023","study_txt":" Completion: 05/04/2023","study_completion_date":" 05/04/2023","last_update_posted":"2024-06-12"},{"id":"607c59af-1fd9-4afc-8491-e33c116441ac","acronym":"PNeoVCA","url":"https://clinicaltrials.gov/study/NCT05269381","created_at":"2022-03-08T17:52:43.258Z","updated_at":"2024-07-02T16:34:26.810Z","phase":"Phase 1/2","brief_title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05269381 - PNeoVCA","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK","pipe":" | ","alterations":" TMB-H","tags":["KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 02/24/2025","primary_completion_date":" 02/24/2025","study_txt":" Completion: 02/24/2026","study_completion_date":" 02/24/2026","last_update_posted":"2024-06-12"},{"id":"c8222add-71ac-46cf-97f8-54e3d1c741e3","acronym":"INTASYL PH-762","url":"https://clinicaltrials.gov/study/NCT06014086","created_at":"2023-08-28T14:08:35.359Z","updated_at":"2024-07-02T16:34:27.237Z","phase":"Phase 1","brief_title":"Intratumoral PH-762 for Cutaneous Carcinoma","source_id_and_acronym":"NCT06014086 - INTASYL PH-762","lead_sponsor":"Phio Pharmaceuticals Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-06-11"},{"id":"4574703b-19bd-4bd3-9dd9-9adace3f6487","acronym":"","url":"https://clinicaltrials.gov/study/NCT05896839","created_at":"2023-06-09T16:06:51.642Z","updated_at":"2024-07-02T16:34:27.634Z","phase":"Phase 1/2","brief_title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","source_id_and_acronym":"NCT05896839","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 08/11/2024","start_date":" 08/11/2024","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"80611a75-8e50-4af0-8595-0b4412326e20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576091","created_at":"2021-01-18T21:50:45.107Z","updated_at":"2024-07-02T16:34:37.303Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","source_id_and_acronym":"NCT04576091","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 11/27/2024","study_completion_date":" 11/27/2024","last_update_posted":"2024-06-07"},{"id":"50b1d2ff-2ef3-453b-9f2f-2564d9c8d558","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616196","created_at":"2021-01-19T20:33:33.968Z","updated_at":"2024-07-02T16:35:04.204Z","phase":"Phase 1/2","brief_title":"Study of NKTR 255 in Combination With Cetuximab in Solid Tumors","source_id_and_acronym":"NCT04616196","lead_sponsor":"Nektar Therapeutics","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • avipendekin pegol (NKTR-255)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2024-05-13"},{"id":"f1ad940d-0158-42e2-8647-51b32c5f7ee6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565417","created_at":"2022-10-04T15:57:50.214Z","updated_at":"2024-07-02T16:35:06.273Z","phase":"Phase 1/2","brief_title":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05565417","lead_sponsor":"Immunitas Therapeutics","biomarkers":" KRAS • BRAF • ALK • PIK3CA • MET • MSI","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation","tags":["KRAS • BRAF • ALK • PIK3CA • MET • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • IMT-009"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-03"},{"id":"cf185d09-6b9d-475d-a594-2be60eaf333a","acronym":"CA209-587","url":"https://clinicaltrials.gov/study/NCT04204837","created_at":"2021-01-18T20:29:01.682Z","updated_at":"2025-02-25T14:28:56.134Z","phase":"Phase 2","brief_title":"Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin","source_id_and_acronym":"NCT04204837 - CA209-587","lead_sponsor":"Salzburger Landeskliniken","biomarkers":" PD-L1 • LAG3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-04-18"},{"id":"682aa921-645e-49b0-82c4-e046257641d9","acronym":"KEYNOTE 630","url":"https://clinicaltrials.gov/study/NCT03833167","created_at":"2021-01-18T18:55:34.724Z","updated_at":"2024-07-02T16:35:09.435Z","phase":"Phase 3","brief_title":"Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)","source_id_and_acronym":"NCT03833167 - KEYNOTE 630","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 05/05/2025","primary_completion_date":" 05/05/2025","study_txt":" Completion: 09/29/2028","study_completion_date":" 09/29/2028","last_update_posted":"2024-04-16"},{"id":"07a51dc9-114c-48cd-acba-f59680179bb5","acronym":"INNATE","url":"https://clinicaltrials.gov/study/NCT04669899","created_at":"2021-07-23T15:52:37.047Z","updated_at":"2024-07-02T16:35:10.864Z","phase":"Phase 1/2","brief_title":"Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04669899 - INNATE","lead_sponsor":"Jounce Therapeutics, Inc.","biomarkers":" EGFR • PD-L1 • ALK • IDH1 • FGFR","pipe":" | ","alterations":" EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation","tags":["EGFR • PD-L1 • ALK • IDH1 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimivalimab (JTX-4014) • polzastobart (JTX-8064)"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 11/28/2023","study_completion_date":" 11/28/2023","last_update_posted":"2024-04-09"},{"id":"31d7ee1a-3f75-40a4-8d61-0c58c2bd4ffc","acronym":"NCI-2018-01399","url":"https://clinicaltrials.gov/study/NCT03108131","created_at":"2021-01-18T15:18:44.409Z","updated_at":"2024-07-02T16:35:11.100Z","phase":"Phase 2","brief_title":"Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors","source_id_and_acronym":"NCT03108131 - NCI-2018-01399","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 04/07/2017","start_date":" 04/07/2017","primary_txt":" Primary completion: 04/02/2024","primary_completion_date":" 04/02/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2024-04-05"},{"id":"a2f75d20-dee9-45ea-9554-ac58b3d9f48d","acronym":"MITRIC","url":"https://clinicaltrials.gov/study/NCT05286294","created_at":"2022-03-18T12:53:40.816Z","updated_at":"2024-07-02T16:35:11.349Z","phase":"Phase 2","brief_title":"Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders","source_id_and_acronym":"NCT05286294 - MITRIC","lead_sponsor":"Oslo University Hospital","biomarkers":" PD-L1 • MSI • LAG3","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • MSI • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/28/2022","start_date":" 06/28/2022","primary_txt":" Primary completion: 03/31/2034","primary_completion_date":" 03/31/2034","study_txt":" Completion: 12/31/2034","study_completion_date":" 12/31/2034","last_update_posted":"2024-04-04"},{"id":"a9577f45-e57c-4142-84ae-067eccfe367a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007744","created_at":"2021-01-18T19:41:36.045Z","updated_at":"2024-07-02T16:35:12.692Z","phase":"Phase 1","brief_title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04007744","lead_sponsor":"Mayo Clinic","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/13/2020","start_date":" 02/13/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-03-26"},{"id":"04584984-e8aa-4f15-9b71-d34c5c6cb62e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03816332","created_at":"2021-01-18T18:51:19.330Z","updated_at":"2024-07-02T16:35:12.938Z","phase":"Phase 1","brief_title":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers","source_id_and_acronym":"NCT03816332","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • prednisone • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 11/08/2019","start_date":" 11/08/2019","primary_txt":" Primary completion: 10/11/2022","primary_completion_date":" 10/11/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"b3f6e3f3-f8b2-4cd5-bf36-ab5083891e9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03590054","created_at":"2021-01-18T17:39:18.307Z","updated_at":"2024-07-02T16:35:13.120Z","phase":"Phase 1","brief_title":"Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT03590054","lead_sponsor":"Rahul Aggarwal","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • abexinostat (CG-781)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2024-03-22"},{"id":"79fc19fa-8e81-4240-8411-e1af2a9cdd37","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084845","created_at":"2023-10-16T15:12:57.739Z","updated_at":"2024-07-02T16:35:14.380Z","phase":"Phase 2","brief_title":"Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer","source_id_and_acronym":"NCT06084845","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" TNFA","pipe":" | ","alterations":" CDKN2A negative","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • xevinapant (Debio 1143)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/12/2024","start_date":" 04/12/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2024-03-15"}]